Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Secondary prevention in young patients after acute ST segment elevation myocardial infarction: missing the goals and suffering the penalties.
Session:
Sessão de Posters 22 - Risco cardiovascular
Speaker:
Miguel Azaredo Raposo
Congress:
CPC 2024
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.14 Risk Factors and Prevention - Other
Session Type:
Cartazes
FP Number:
---
Authors:
Miguel Azaredo Raposo; Ana Abrantes; Graça Araújo; Daniela Roxo; José Costa; José Poupino; Rita Pinto; Madalena Lemos Pires; Silvia Fiuza; Inês Ricardo; Ana Abreu; Fausto J. Pinto
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Introduction</span></span></span></strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">: Young patients that suffer an acute ST segment elevation myocardial infarction (STEMI) are an especially vulnerable population that requires close monitoring. Therefore, secondary prevention in these pts is key to prevent event recurrency during their lifetime.</span></span></span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Purpose</span></span></span></strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">: To evaluate efficacy of risk factor control in a population of young pts with STEMI.</span></span></span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Methods</span></span></span></strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">: Retrospective, single-center study of consecutive pts, aged below 50 years, admitted with STEMI between 2017 and 2021. Demographics, clinical characteristics and outcomes were analyzed. Parametric and non-parametric tests were performed as appropriate.</span></span></span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Results</span></span></strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">: We included 306 pts, 81.7% were men, mean age of 43.9 ± 5.1 years, the majority was admitted with anterior followed by inferior STEMI. Only 26pts were previously under statin therapy, median cLDL at admission was 105±47. </span></span><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">At discharge all pts were under statins however only 63% received high intensity statin and 4% ezetimibe. Only 20% of pts completed a cardiac rehabilitation program.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">During a mean follow-up (FUP) of 3.8 ± 1.7 years, 52.3% of pts had less than optimal controlled hypertension, 20.7% had diabetes, 53% still smoked, cLDL was significantly lower, (mean of 86 ± 39, p<0.001), with a mean reduction of 26.8% ± 46.6.</span></span> <span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">High intensity statin was prescribed to 54% of pts, ezetimibe to 33%, the combination of high intensity statin and ezetimibe to 22%, no one was under iPCSK9 or bempedoic acid.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">However, only 16.8% of pts met guideline-oriented goal of cLDL<55mg/dl, and only 26.9% presented a 50% reduction from baseline cLDL. In pts with cLDL>55mg/dl only 47.7% were under high intensity statin, 33% under ezetimibe and 30.4% under high intensity statin plus ezetimibe, up titration occurred in about 30% of these pts. When considering pts under high intensity statin and ezetimibe only 23.7% met cLDL goal.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">During FUP, 19 pts had reinfarction and of these only 5.3% of pts met target cLDL and half were under therapy with high intensity statin and ezetimibe. When considering the 25 pts who died, no one had cLDL<55 nor anyone was under high intensity statin plus ezetimibe.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Conclusion</span></span></span></strong><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">: Secondary prevention in coronary patients, namely young ones, must be strengthened; cardiac rehabilitation referral and completion of programs has to be optimized and special focus on cardiovascular risk factors control must be made in order to achieve guideline recommended targets and reduce adverse events during follow-up.</span></span></span></span></span></span></span></p> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> <div id="accel-snackbar" style="left:50%; top:50px; transform:translate(-50%, 0px)"> </div>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site